Direct reprogramming of hepatocytes into JAK/Stat-dependent LGR5+ liver cells able to initiate intrahepatic cholangiocarcinoma.

ICC LGR5 WNT/βcatenin liver

Journal

Stem cells (Dayton, Ohio)
ISSN: 1549-4918
Titre abrégé: Stem Cells
Pays: England
ID NLM: 9304532

Informations de publication

Date de publication:
23 Jan 2024
Historique:
received: 13 07 2023
medline: 24 1 2024
pubmed: 24 1 2024
entrez: 23 1 2024
Statut: aheadofprint

Résumé

Somatic cells that have been partially reprogrammed by the factors Oct4, Sox2, Klf4, and cMyc (OSKM) have been demonstrated to be potentially tumorigenic in vitro and in vivo due to the acquisition of cancer-associated genomic alterations and the absence of OSKM clearance over time. In the present study we obtained partially reprogrammed, SSEA1-negative cells by transducing murine hepatocytes with Δ1Δ3-deleted adenoviruses that expressed the four OSKM factors. We observed that, under long-term 2D and 3D culture conditions, hepatocytes could be converted into LGR5-positive cells with self-renewal capacity that was dependent on three cross-signaling pathways: IL6/Jak/Stat3, LGR5/R-spondin, and Wnt/β-catenin. Following engraftment in syngeneic mice, LGR5-positive cells that expressed the cancer markers CD51, CD166, and CD73 were capable of forming invasive and metastatic tumors reminiscent of intrahepatic cholangiocarcinoma (ICC): they were positive for CK19 and CK7, featured associations of cord-like structures, and contained cuboidal and atypical cells with dissimilar degrees of pleomorphism and mitosis. The LGR5+-derived tumors exhibited a highly vascularized stroma with substantial fibrosis. In addition, we identified pro-angiogenic factors and signaling pathways involved in neo-angiogenesis and vascular development, which represent potential new targets for anti-angiogenic strategies to overcome tumor resistance to current ICC treatments.

Identifiants

pubmed: 38262709
pii: 7585862
doi: 10.1093/stmcls/sxae006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Diana Chaker (D)

Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS 1310, Villejuif, France.
Institut National de la Santé et de la Recherche Médicale (INSERM) UMS 045- CITHERA 'Center for iPSC Cell Therapy,' National Infrastructure INGESTEM, Corbeil-Essonnes, Evry France.

Christophe Desterke (C)

Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS 1310, Villejuif, France.
Université Paris-Saclay, Faculté de Médecine Kremlin Bicêtre, France.

Nicolas Moniaux (N)

Université Paris-Saclay, Faculté de Médecine Kremlin Bicêtre, France.
Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS1193, Villejuif, France.

Mohamed-Amine Bani (MA)

Institut Gustave-Roussy, Département de Biologie et Pathologie Médicale, service de pathologie morphologique, Villejuif, France.
Université Paris-Saclay, Gustave Roussy Cancer Centre, Inserm US23, CNRS UMS3655, AMMICa, Villejuif, France.

Noufissa Oudrhiri (N)

Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS 1310, Villejuif, France.
Institut National de la Santé et de la Recherche Médicale (INSERM) UMS 045- CITHERA 'Center for iPSC Cell Therapy,' National Infrastructure INGESTEM, Corbeil-Essonnes, Evry France.
Service d'Hématologie Biologique Laboratoire d'Onco-Hematologie moleculaire et Cytogénetique APHP, Hôpital Universitaire Paris Sud Paul-Brousse, 94805 Villejuif, France.

Jamila Faivre (J)

Université Paris-Saclay, Faculté de Médecine Kremlin Bicêtre, France.
Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS1193, Villejuif, France.
Service d'Hématologie Biologique Laboratoire d'Onco-Hematologie moleculaire et Cytogénetique APHP, Hôpital Universitaire Paris Sud Paul-Brousse, 94805 Villejuif, France.

Ali G Turhan (AG)

Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS 1310, Villejuif, France.
Institut National de la Santé et de la Recherche Médicale (INSERM) UMS 045- CITHERA 'Center for iPSC Cell Therapy,' National Infrastructure INGESTEM, Corbeil-Essonnes, Evry France.
Université Paris-Saclay, Faculté de Médecine Kremlin Bicêtre, France.
Service d'Hématologie Biologique Laboratoire d'Onco-Hematologie moleculaire et Cytogénetique APHP, Hôpital Universitaire Paris Sud Paul-Brousse, 94805 Villejuif, France.
Service d'Hématologie Biologique, Hôpital Universitaire Paris Sud, (AP-HP) 94 Kremlin Bicêtre, France.

Annelise Bennaceur-Griscelli (A)

Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS 1310, Villejuif, France.
Institut National de la Santé et de la Recherche Médicale (INSERM) UMS 045- CITHERA 'Center for iPSC Cell Therapy,' National Infrastructure INGESTEM, Corbeil-Essonnes, Evry France.
Université Paris-Saclay, Faculté de Médecine Kremlin Bicêtre, France.
Service d'Hématologie Biologique Laboratoire d'Onco-Hematologie moleculaire et Cytogénetique APHP, Hôpital Universitaire Paris Sud Paul-Brousse, 94805 Villejuif, France.

Frank Griscelli (F)

Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS 1310, Villejuif, France.
Institut National de la Santé et de la Recherche Médicale (INSERM) UMS 045- CITHERA 'Center for iPSC Cell Therapy,' National Infrastructure INGESTEM, Corbeil-Essonnes, Evry France.
Institut Gustave-Roussy, Département de Biologie et Pathologie Médicale, service de pathologie morphologique, Villejuif, France.
Université Paris Descartes, Sorbonne Paris Cité, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France.

Classifications MeSH